MONTREAL, Oct. 30 /PRNewswire-FirstCall/ - CryoCath Technologies Inc.(TSX: CYT), the global leader in cryotherapy products to treat cardiacarrhythmias, today announced that Jan Keltjens, President and CEO of CryoCath,will present at the 18th Annual CIBC Healthcare Conference at the WaldorfAstoria in New York City on Tuesday, November 6. Mr. Keltjens will present acorporate update, as well as provide updates on the STOP AF IDE Trial forArctic Front(R), the Company's minimally invasive cryo-balloon catheterdesigned specifically to treat paroxysmal atrial fibrillation.
A live webcast of CryoCath's presentation will be available atwww.cryocath.com.
CryoCath - www.cryocath.com - is a medical technology company that leadsthe world in cryotherapy products to treat cardiovascular disease. With apriority focus on providing physicians with a complete solution of catheterproducts to treat cardiac arrhythmias, CryoCath has multiple products approvedin the U.S., across Europe and several ROW countries. The Company isdeveloping additional products to expand its pipeline of products to treatcardiac arrhythmias.
This press release includes "forward-looking statements" that are subjectto risks and uncertainties, including with respect to the timing of regulatorytrials and their outcome. For information identifying legislative orregulatory, economic, climatic, currency, technological, competitive and otherimportant factors that could cause actual results to differ materially fromthose anticipated in the forward looking statements, see CryoCath's annualreport available at www.sedar.com under the heading Risks and Uncertainties inthe Management's Discussion and Analysis section.
SOURCE CryoCath Technologies Inc.